Last reviewed · How we verify
CRB-601 monoclonal antibody
CRB-601 monoclonal antibody is a Small molecule drug developed by Corbus Pharmaceuticals Inc.. It is currently in Phase 1 development.
At a glance
| Generic name | CRB-601 monoclonal antibody |
|---|---|
| Sponsor | Corbus Pharmaceuticals Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CRB-601 monoclonal antibody CI brief — competitive landscape report
- CRB-601 monoclonal antibody updates RSS · CI watch RSS
- Corbus Pharmaceuticals Inc. portfolio CI
Frequently asked questions about CRB-601 monoclonal antibody
What is CRB-601 monoclonal antibody?
CRB-601 monoclonal antibody is a Small molecule drug developed by Corbus Pharmaceuticals Inc..
Who makes CRB-601 monoclonal antibody?
CRB-601 monoclonal antibody is developed by Corbus Pharmaceuticals Inc. (see full Corbus Pharmaceuticals Inc. pipeline at /company/corbus-pharmaceuticals-inc).
What development phase is CRB-601 monoclonal antibody in?
CRB-601 monoclonal antibody is in Phase 1.